scholarly journals Patient-relevant Endpoints in Inflammatory Bowel Diseases - Have Changes Occurred in Germany over the Past Twelve Years?

2015 ◽  
Vol 9 (5) ◽  
pp. 390-397 ◽  
Author(s):  
A. Stallmach ◽  
U. Dennler ◽  
U. Marschall ◽  
C. Schmidt
Keyword(s):  
Inflammatory Bowel Diseases ◽  
The Past ◽  
Bowel Diseases ◽  
Inflammatory Bowel

scholarly journals Management of Musculoskeletal Manifestations in Inflammatory Bowel Disease

2015 ◽  
Vol 2015 ◽  
pp. 1-11 ◽  
Author(s):  
Tejas Sheth ◽  
C. S. Pitchumoni ◽  
Kiron M. Das
Keyword(s):  
Inflammatory Bowel Diseases ◽  
Multidisciplinary Approach ◽  
Physical Therapist ◽  
Cost Savings ◽  
The Past ◽  
The Us ◽  
Bowel Diseases ◽  
Musculoskeletal Manifestations ◽  
Inflammatory Bowel ◽  
Near Future

Musculoskeletal manifestations are the most common extraintestinal manifestations in inflammatory bowel diseases. Some appendicular manifestations are independent of gut inflammation and are treated with standard anti-inflammatory strategies. On the other hand, axial involvement is linked to gut inflammatory activity; hence, there is a considerable amount of treatment overlap. Biological therapies have revolutionized management of inflammatory bowel diseases as well as of associated articular manifestations. Newer mechanisms driving gut associated arthropathy have surfaced in the past decade and have enhanced our interests in novel treatment targets. Introduction of biosimilar molecules is expected in the US market in the near future and will provide an opportunity for considerable cost savings on healthcare. A multidisciplinary approach involving a gastroenterologist, rheumatologist, and physical therapist is ideal for these patients.

scholarly journals Methotrexate for Inflammatory Bowel Diseases - New Developments

2016 ◽  
Vol 34 (1-2) ◽  
pp. 140-146 ◽  
Author(s):  
Hans H. Herfarth
Keyword(s):  
Ulcerative Colitis ◽  
Crohn’S Disease ◽  
Inflammatory Bowel Diseases ◽  
Antibody Formation ◽  
Clinical Effectiveness ◽  
New Developments ◽  
The Past ◽  
Steroid Dependent ◽  
Bowel Diseases ◽  
Inflammatory Bowel

Methotrexate (MTX) is an established therapy for patients with steroid-dependent Crohn's disease (CD). MTX is also frequently used in combination with anti-TNF agents to suppress anti-drug antibody formation. It has been suggested in the past that MTX lacks any clinical effectiveness in patients with ulcerative colitis (UC); however, newer data at least partially contradict this assumption. The following review will discuss recent data for the use of MTX in CD, UC and in combination with anti-TNF agents.

scholarly journals Epidemiology and diagnosis of inflammatory bowel diseases

2021 ◽  
Vol 64 (9) ◽  
pp. 579-587
Author(s):  
Kang-Moon Lee
Keyword(s):  
Inflammatory Bowel Diseases ◽  
Public Awareness ◽  
Intestinal Tuberculosis ◽  
Diagnostic Delay ◽  
Perianal Fistula ◽  
Diagnostic Tools ◽  
Male Predominance ◽  
The Past ◽  
Bowel Diseases ◽  
Inflammatory Bowel

Background: Over the past three decades, inflammatory bowel diseases (IBD) have been rapidly increasing in the African, South American, and Asian countries, including Korea. However, in Korea, the public awareness of IBD remains low, and diagnostic delay is not uncommon due to the physicians' lack of clinical experience. It is essential to understand the trends and regional differences in the epidemiology of IBD for proper diagnosis and treatment.Current Concepts: Although lower than those of the West, the prevalence and incidence of IBD in Korea rank among the highest in Asia and are steadily increasing. In the past 10 years, the prevalence of IBD has almost doubled, while its incidence has decreased gradually. As compared to Western IBD patients, Korean patients have higher proportion of proctitis in ulcerative colitis, male predominance, more ileocolonic involvement, and higher incidence of perianal fistula in Crohn disease. There is no single gold standard for the diagnosis of IBD. Thus, diagnosis can be made by clinical evaluation, including a detailed history taking, physical examination, and a combination of endoscopic, radiologic, laboratory, and histologic findings.Discussion and Conclusion: Population-based studies have revealed the current trends and characteristics of the epidemiology of IBD in Korea. Continued education and development of diagnostic tools will help clinicians to diagnose IBD accurately and differentiate it from other diseases such as intestinal tuberculosis.

scholarly journals Bioactivity of Polyphenols: Preventive and Adjuvant Strategies toward Reducing Inflammatory Bowel Diseases—Promises, Perspectives, and Pitfalls

2016 ◽  
Vol 2016 ◽  
pp. 1-29 ◽  
Author(s):  
Anouk Kaulmann ◽  
Torsten Bohn
Keyword(s):  
Inflammatory Bowel Diseases ◽  
Short Chain Fatty Acid ◽  
Current Knowledge ◽  
Gut Permeability ◽  
Metabolizing Enzymes ◽  
Cellular Targets ◽  
The Past ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Cytokine Formation

Inflammatory bowel diseases (IBDs) are characterized by autoimmune and inflammation-related complications of the large intestine (ulcerative colitis) and additional parts of the digestive tract (Crohn’s disease). Complications include pain, diarrhoea, chronic inflammation, and cancer. IBD prevalence has increased during the past decades, especially in Westernized countries, being as high as 1%. As prognosis is poor and medication often ineffective or causing side effects, additional preventive/adjuvant strategies are sought. A possible approach is via diets rich in protective constituents. Polyphenols, the most abundant phytochemicals, have been associated with anti-inflammatory, antioxidant, immunomodulatory, and apoptotic properties. Locally reducing oxidative stress, they can further act on cellular targets, altering gene expression related to inflammation, including NF-κB, Nrf-2, Jak/STAT, and MAPKs, suppressing downstream cytokine formation (e.g., IL-8, IL-1β, and TNF-α), and boosting the bodies’ own antioxidant status (HO-1, SOD, and GPx). Moreover, they may promote, as prebiotics, healthy microbiota (e.g., Bifidobacteria,Akkermansia), short-chain fatty acid formation, and reduced gut permeability/improved tight junction stability. However, potential adverse effects such as acting as prooxidants, or perturbations of efflux transporters and phase I/II metabolizing enzymes, with increased uptake of undesired xenobiotics, should also be considered. In this review, we summarize current knowledge around preventive and arbitrary actions of polyphenols targeting IBD.

scholarly journals POS1236 IMPACT OF COVID-19 ON INITIATION AND RENEWAL OF BIOTHERAPIES AND TARGETED SYNTHETIC TREATMENTS

2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 901.1-901
Author(s):  
P. Richette ◽  
M. Allez ◽  
V. Descamps ◽  
L. Perra ◽  
S. Pilet ◽  
...  
Keyword(s):  
Inflammatory Bowel Diseases ◽  
Outpatient Care ◽  
Subcutaneous Injection ◽  
Inflammatory Diseases ◽  
Jak Inhibitors ◽  
Scientific Societies ◽  
The Past ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
The Impact

Background:During the epidemic’s peak of COVID-19, scientific societies published recommendations on biotherapy and targeted synthetic treatment (B/TST) use in patients with chronic articular inflammatory diseases, inflammatory bowel diseases, and psoriasis.Objectives:The objective was to evaluate the impact of COVID-19 in France on initiation and renewal of B/TST.Methods:LRx contains all anonymized medication dispenses prescribed in outpatient care in a representative panel of French retails pharmacies, including data of near 40 million patients. The impact of B/TST initiation and renewal were studied using 2019 as reference and dispense deliveries data of pharmacies with regular flew in order to perform the comparison. B/TST considered were abatacept, anti-TNF, anti-IL6, anti-IL17, anti-IL12/23 or anti-IL23, JAK inhibitors (JAKi) and other classes such as aprelimast, aminosalicylates (AS), hydroxychloroquine (HCQ), and methotrexate (MTX). A treatment initiated was defined as a treatment not delivered in the past 12 months, and conversely for a treatment renewal. Results were presented as raw one and expressed in percentage of patients having at least one B/TST delivery in each therapeutic classes of interest in 2020 compared to 2019 used as reference year (period from week 12 to week 19 considered and corresponding to the lockdown period in France).Results:During the lockdown period, a decrease in initiation was observed for patients treated with: abatacept (405 in 2019 vs 227 in 2020: -44%, p<0.001), anti-TNF (1156 vs 1058, -31%, p<0.001), anti-IL17 (415 vs 206, -50%, p<0.001), anti-IL12-23 (395 vs 339, -12%, p=0.16), JAKi (289 vs 174, -39%, p=0.006), contrasting with an increase for Tociliumab (117 vs 445, +152%, p=0,01). We found a decrease of 7% (2171 vs 2015, p=0,35), 44% (405 vs 227, p<0.001), 30% (3430 vs 2390, p p<0.001) of AS, aprelimast and MTX initiation, respectively, and an increase of 173% (1708 vs 4671, p=0.11) of HCQ initiation. No decrease for the renewal of B/TST was observedConclusion:During the epidemic’s peak, initiation of AS, MTX, biotherapies (except for tocilizumab), and JAKi dramatically decreased without impacting their renewal. Two treatments were mainly initiated, tocilizumab probably due to a switch from intravenous to subcutaneous injection and HCQ in relation to its presumably effect on COVID-19. Overall, recommendations from scientific societies have been followed.Disclosure of Interests:None declared

Sign in / Sign up

Export Citation Format

Share Document